This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Partnering, Business Development & Licensing
search
Drug Dev

Acesion tackles atrial fibrillation through SK channel inhibition

Posted by on 15 March 2018
Share this article


Acesion Pharma is focusing on SK channel inhibition to develop safer and more effective drugs to treat and prevent atrial fibrillation. During BIO-Europe Spring 2018, Acesion CEO Frans Wuite described to Scrip his partnering and financing ambitions for the lead program which is entering Phase I testing.

Share this article

Sign up for Partnering, Business Development & Licensing email updates

keyboard_arrow_down